MDT-BRIDGE II 期：新辅助 durvalumab 联合化疗用于可切除及临界可切除 NSCLC
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial
ESMO 2026 公布的全球 II 期 MDT-BRIDGE 试验显示，可切除及临界可切除非小细胞肺癌患者接受新辅助 durvalumab 联合化疗并经多学科再评估后，多数患者得以接受手术，病理完全缓解率令人鼓舞。不可切除肿瘤患者继续接受放化疗联合 durvalumab 巩固治疗，未报告额外安全性问题。
Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04742-7
As presented at the ESMO Congress 2026: In the global phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy in patients with resectable and borderline resectable non-small-cell lung cancer, followed by multidisciplinary reassessment, enabled surgery in most patients, leading to encouraging pathological complete response rates, and no additional safety concerns were reported when patients with unresectable tumors continued with chemoradiotherapy and consolidative durvalumab.
来源：Nature Medicine · nature.com